Search

The most common form of cancer among women is metastatic breast cancer. One of the world's three most common cancers, it is the second leading cause of death in the United States, following lung cancer. A plethora of drugs are available for breast cancer treatment. One of the promising new candidates for this type of tumor is Kisquali (Ribociclib), a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor. Ribociclib was recently developed by Novartis and approved by the USFDA under the trade name of "Kisquali" for the treatment of advanced receptor hormone positive (HR+), an inhibitor of human epidermal growth factor 2-negative cancer (HER2-). It functions by phosphorylation inhibition and can decrease the count of CDK4/6. In addition, Ribociclib also shows different interactions since the metabolism of the drug can be changed by enzyme inducers and inhibitors. Ribociclib was tested for multiple solid tumors and lymphomas in Phase I and II trials and further underwent Phase III studies in breast cancer. Results from Phase I and II trials on positive estrogen receptor (ER1) breast cancer indicate promising efficacy with controlled toxic effects, primarily neutropenia. All the successful approaches of this promising candidate are underlined in this study. [ABSTRACT FROM AUTHOR]